🔗 Share this article

A shadow market for unlicensed slimming drugs is being driven by social media fitness personalities and vendors on messaging platforms, according to new investigations.

Experimental Drug Gaining Traction Online

The experimental drug, which remains in research studies, is being advertised by online personalities for its alleged fat-burning effects. Followers are urged to message these accounts privately for supplier links, while also receiving discount codes.

Thriving Commerce on Messaging Platforms

Separately, a robust market exists on Telegram, where groups with thousands of members share “before and after” photos, administration instructions and assertions of rapid UK delivery. Vendors promote the drug there before redirecting customers to other platforms for purchases.

Understanding Retatrutide

Retatrutide is an experimental injectable created by American pharmaceutical company Eli Lilly. The treatment targets three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could help patients reduce up to a quarter of their body weight. Nicknamed the “triple G”, the drug is being promoted digitally as the next Ozempic.

Medical Professionals Express Concerns

However, physicians and pharmacists have cautions that the sale of what is still an unlicensed medication in the United Kingdom is worrisome and could result in users injecting substances of uncertain source.

Several professionals stated the popularity for the experimental drug could be linked to the increasing price of licensed slimming treatments such as Mounjaro.

Regulatory Status and Implementation

Marketing the unapproved drug on social media or Telegram is prohibited in the United Kingdom, as it is an unlicensed drug that must not be promoted or supplied for personal consumption under the Human Medicines Regulations 2012.

Some content creators try to circumvent the rules by calling to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled substance, but promotion and distribution can still breach pharmaceutical, marketing, and consumer regulations, risking fines, prosecution or imprisonment.

Service Reaction and Material Removal

According to the social media company, the platform has removed problematic content and banned related keywords and query recommendations. The company stated it was dedicated to keeping the platform safe and investing in strengthening compliance measures.

Online Trading Operations

Research also discovered groups with up to nine thousand participants marketing the experimental drug using Telegram's integrated discovery tool, which functions like a online catalog. Entering “retatrutide” instantly displays groups with thousands of members, populated with photos of weight loss, positive testimonials and step-by-step instructions for preparing or administering at residence.

After moments of entering one community, a seller posted WhatsApp details, where most transactions take place. The vendor provided an guidebook and promised delivery within two days. When asked whether the product was genuine, one vendor said: “You can’t be sure.” Another shared a image of a alleged laboratory certificate. Not one asked about weight, medical conditions or past usage.

Product Information and Pricing

Within these communities, posts show black plastic packages with postal service stickers, claiming to include new batches. One communication read: “It took eight of us to load them this morning.”

Customers can select between powder vials, prepared at residence with purified liquid, or ready-to-use pens typically priced at £160 for 20 milligrams. When questioned how much time a pen should last, vendors give conflicting answers ranging from a several days to “depends on your body”.

Service Oversight and Security Actions

A spokesperson for Telegram said it regularly moderated harmful material on its platform including content that encouraged the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Cautions

“Individuals are injecting substances they cannot confirm. Although the research behind retatrutide is sound, these online versions may not include what they advertise,” said Jason Murphy, the head of pharmaceutical services at a pharmacy service.

A medical professional of Asda Online Doctor connected the surge in interest to current price rises for approved weight-loss drugs such as Mounjaro. “With costs rising, individuals are turning to social media. But counterfeit treatments are extremely risky. You cannot know what’s inside or whether the conditions they were produced in was sterile,” she said.

Her staff has already encountered individuals injured by personal administration from unconfirmed sources. “We recognize the disappointment, but buying from messaging apps or WhatsApp is taking chances with your health,” stated the doctor. “These materials could be impure or incorrectly dosed.”

Manufacturer Statement

A representative from the pharmaceutical company said retatrutide was in phase 3 research studies and had not been reviewed or authorized by any regulatory agency anywhere in the world. “Therefore at this time no one can sell [it] for personal consumption,” they explained, adding that any item “falsely representing itself as a company investigational product not yet approved … may subject users to possibly significant medical dangers”.